Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVX201 in Hospitalized COVID-19
NCT04900454Phase 1Completed
- Sponsor
- Coeptis Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic natural killer cells DVX201 in coronavirus disease 2019 (COVID-19), sponsored by Coeptis Pharmaceuticals. Primary endpoint: Incidence of Dose Limiting Toxicities at 7 days. Started Aug 2021; status: completed.
02
Drugs
allogeneic natural killer cells DVX201
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04900454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900454.